Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobin
- Christian Medical College, India
- Gladstone Institutes, United States
- University of California, Berkeley, United States
- University of New South Wales, Australia
- Christian Medical College & Hospital, India
- RIKEN BioResource Center, Japan
- Japanese Red Cross Society, Japan, Japan
- University of California, Los Angeles, United States
- ETH Zurich, Switzerland
Abstract
Naturally occurring point mutations in the HBG promoter switch hemoglobin synthesis from defective adult beta-globin to fetal gamma-globin in sickle-cell patients with hereditary persistence of fetal hemoglobin (HPFH) and ameliorate the clinical severity. Inspired by this natural phenomenon, we tiled the highly homologous HBG proximal promoters using adenine and cytosine base editors that avoid the generation of large deletions and identified novel regulatory regions including a cluster at the -123 region. Base editing at -123 and -124bp of HBG promoter induced HbF to a higher level than disruption of well-known BCL11A binding site in erythroblasts derived from human CD34+ HSPC. We further demonstrated in vitro that the introduction of -123T>C and -124T>C HPFH-like mutations drives gamma-globin expression by creating a de novo binding site for KLF1. Overall, our findings shed light on so far unknown regulatory elements within the HBG promoter and identified additional targets for therapeutic upregulation of fetal hemoglobin.
Data availability
The transcriptome data have been deposited in GEO under accession code GSE192801All the raw data from this study have been deposited in Dyrad (doi:10.5061/dryad.bzkh1897h).
-
Data from: Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobinDryad Digital Repository, doi:10.5061/dryad.bzkh1897h.
Article and author information
Author details
Henry William Bell
Kumarasamypet Murugesan Mohankumar
Funding
Department of Biotechnology, Ministry of Science and Technology, India (BT/PR17316/MED/31/326/2015)
- Kumarasamypet Murugesan Mohankumar
National Health and Medical Research Council (National Health and Medical Research Council (NHMRC))
- Henry William Bell
National Health and Medical Research Council (Grant)
- Merlin Crossley
Science and Engineering Research Board (EMR/2017/004363)
- Kumarasamypet Murugesan Mohankumar
Indo-US Science and Technology Forum (Indo-U.S. GETin Fellowship_2018_066)
- Kumarasamypet Murugesan Mohankumar
Department of Biotechnology, Ministry of Science and Technology, India (BT/PR38392/GET/119/301/2020)
- Kumarasamypet Murugesan Mohankumar
Council of Scientific and Industrial Research, India (Senior Research Fellow)
- Nithin Sam Ravi
Council of Scientific and Industrial Research, India (Senior Research Fellow)
- Anila George
Department of Biotechnology, Ministry of Science and Technology, India (Senior Research Fellow)
- Vignesh Rajendiran
National Health and Medical Research Council (Early Career Research Fellowship)
- Beeke Wienert
Department of Biotechnology, Ministry of Science and Technology, India (BT/PR25841/GET/119/162/2017)
- Srujan Marepally
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Human subjects: The left-over peripheral blood mononuclear cells (PBMNC) were obtained from a healthy donor after infusion according to the clinical protocols approved by the Intuitional Review Boards of Christian Medical College, Vellore.IRB Min. No. 12309 (OTHER) dated 30. 10.2019
Copyright
© 2022, Ravi et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 5,302
- views
-
- 639
- downloads
-
- 38
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobin
eLife 11:e65421.
https://doi.org/10.7554/eLife.65421
Further reading
-
- Chromosomes and Gene Expression
- Neuroscience
Pathogenic variants in subunits of RNA polymerase (Pol) III cause a spectrum of Polr3-related neurodegenerative diseases including 4H leukodystrophy. Disease onset occurs from infancy to early adulthood and is associated with a variable range and severity of neurological and non-neurological features. The molecular basis of Polr3-related disease pathogenesis is unknown. We developed a postnatal whole-body mouse model expressing pathogenic Polr3a mutations to examine the molecular mechanisms by which reduced Pol III transcription results primarily in central nervous system phenotypes. Polr3a mutant mice exhibit behavioral deficits, cerebral pathology and exocrine pancreatic atrophy. Transcriptome and immunohistochemistry analyses of cerebra during disease progression show a reduction in most Pol III transcripts, induction of innate immune and integrated stress responses and cell-type-specific gene expression changes reflecting neuron and oligodendrocyte loss and microglial activation. Earlier in the disease when integrated stress and innate immune responses are minimally induced, mature tRNA sequencing revealed a global reduction in tRNA levels and an altered tRNA profile but no changes in other Pol III transcripts. Thus, changes in the size and/or composition of the tRNA pool have a causal role in disease initiation. Our findings reveal different tissue- and brain region-specific sensitivities to a defect in Pol III transcription.
-
- Biochemistry and Chemical Biology
- Chromosomes and Gene Expression
The mRNA 5'-cap structure removal by the decapping enzyme DCP2 is a critical step in gene regulation. While DCP2 is the catalytic subunit in the decapping complex, its activity is strongly enhanced by multiple factors, particularly DCP1, which is the major activator in yeast. However, the precise role of DCP1 in metazoans has yet to be fully elucidated. Moreover, in humans, the specific biological functions of the two DCP1 paralogs, DCP1a and DCP1b, remain largely unknown. To investigate the role of human DCP1, we generated cell lines that were deficient in DCP1a, DCP1b, or both to evaluate the importance of DCP1 in the decapping machinery. Our results highlight the importance of human DCP1 in decapping process and show that the EVH1 domain of DCP1 enhances the mRNA-binding affinity of DCP2. Transcriptome and metabolome analyses outline the distinct functions of DCP1a and DCP1b in human cells, regulating specific endogenous mRNA targets and biological processes. Overall, our findings provide insights into the molecular mechanism of human DCP1 in mRNA decapping and shed light on the distinct functions of its paralogs.
